Acute Coronary Syndrome Clinical Trial
Official title:
Exacerbation of Coronary Heart Disease: the Logic and Probabilistic Processes of Flow Prediction for Optimization of Treatment
The aim of the study is developing an individualized risk model for the unfavorable outcomes
of coronary artery disease and complications from ongoing therapy, according to clinical,
instrumental, biochemical and genetic parameters in patients with acute coronary syndrome.
Inclusion criteria: patients with acute coronary syndrome (with or without ST elevation) who
have indications for PCI Number of inclusion patients - 1655 patients Scheduled time of
follow up - 24 month Primary end-point: all-cause death Secondary end-points: any
cardiovascular events (cardiovascular death, nonfatal myocardial infarction, non-fatal
stroke); non-fatal myocardial infarction; recurrent acute coronary syndrome; non-fatal stoke;
complicated atherosclerosis; recurrent PCI; bleeding
The role of genetic factors in the development of coranary heart disease (CHD) exacerbations
studied not enough. Most research in this area planned and carried out on a "case-control".
Using a similar protocol entails significant errors are associated with a high incidence of
subclinical atherosclerotic vascular lesions. Moreover, much of atheroma is extravasal,
making it impossible to identify them by angiography. Therefore, necessary to conduct
prospective studies to estimate the frequency of so-called hard endpoints. Previously,
similar trials were conducted, mainly in connect with drug approving procedures. The spread
data from them to other patients directly is not entirely justified. At the same time, the
influence of genetic factors in this group of patients can be substantial.
In the previous part of the study, the sample of patients of Moscow, St. Petersburg, Kazan,
Chelyabinsk, Stavropol, Perm, and Rostov-on-the-Don was formed, of 1,200 people admitted due
to acute coronary syndrome (ACS) including unstable angina and acute myocardial infarction,
at coronary care units with follow-up for three years. We found several factors, including
genetic, that significantly affect the outcomes of the disease. Coronary atherosclerosis and
its complications now considered as a multifactorial disease associated with inherent
factors. Therefore, the project provides, besides accounting a significant amount of clinical
and instrumental data, the determination of a wide range of genotypes and alleles of
polymorphic markers candidate genes encoding the protein factors of the hemostatic system,
enzymes of lipid metabolism system, and anti-inflammatory cytokines. It is assumed that the
prediction outcomes of coronary heart disease should be carried out taking into account the
fact that several factors (gender, diabetes, age, aortic stenosis, atrial fibrillation, etc.)
can not only significantly change the forecast itself but also affecting the significance of
other risk factors. Since the last study, the standards significantly of ACS management
changed. Invasive treatment not only creates opportunities to reduce coronary mortality but
also increased demands on the patient's adherence to the assigned medication and creates
additional risks associated with its activity (especially with an antithrombotic treatment
activity). In these circumstances, the development of personalized approaches to prescribing
drugs is particularly important. Thus, the prediction of coronary heart disease outcomes
after an ACS on a set of clinical, instrumental, biochemical and genetic indicators is of
great importance, as it allows to plan the most optimal treatment for the individual patient.
The aim of the study was to develop a model of individualized risk of coronary heart disease
outcomes and side effects of therapy based on clinical and instrumental, biochemical, and
genetic parameters in patients with ACS.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Completed |
NCT02673437 -
Rivaroxaban ACS Specialist Cohort Event Monitoring Study
|